Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of computerized dynamic posturography (CDP) for diagnosing vestibular disorders in adults with signs and symptoms suggesting vestibular disorder, compared with standard otoneurologic tests. While other Hayes reports have more b…
Focus of the Report: The focus of this Health Technology Assessment (HTA) is to evaluate the effectiveness and safety of conventional (i.e., continuous, thermal) radiofrequency ablation (RFA) for sacroiliac joint (SIJ) denervation for the treatment of chronic low back pain (CLBP) thought to arise from the SIJ.
Rebyota (fecal microbiota, live-jslm) is a ready-to-use enema product for fecal microbiota transplantation indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.
EB-101 is an autologous gene-corrected skin graft under investigation for the treatment of chronic open wounds in patients with recessive dystrophic epidermolysis bullosa.
Etranacogene dezaparvovec (Hemgenix; formerly AMT-061) is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
Blarcamesine (ANAVEX 2-73) is an investigational oral drug that targets sigma-1 and muscarinic receptors. It is in development for the treatment of Rett syndrome as well as for a number of other central nervous system disorders.
The Flowsense device is a wireless, noninvasive thermal flow sensor in development for the detection of flow in implanted cerebrospinal fluid shunts in patients with hydrocephalus.
Focus of the Report: This Health Technology Assessment (HTA) focuses on high-intensity focused ultrasound (HIFU) for primary treatment of localized prostate cancer (PCa).
Technology Description: HIFU is a minimally invasive treatment that ablates malignant prostatic tissue using high-i…
Teplizumab is an intravenously administered anti-CD3 monoclonal antibody indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with stage 2 T1D.
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the Evoke SCS System for pain reduction and decreased opioid use related to chronic intractable back and leg pain.